IMMUNOME INC (IMNM)
Health Care · biotechnology · NASDAQ
Immunome is a clinical-stage biotechnology company leveraging a proprietary platform to discover and develop novel, targeted oncology therapeutics.
What IMMUNOME INC does
Immunome is a biotechnology company focused on the discovery and development of targeted oncology therapies. The company utilizes a proprietary technology platform to identify and develop novel antibody-based treatments for cancer.
Themes: oncology, drug discovery, biotechnology, targeted cancer therapy
Fundamentals
- Price$28.01 as of 2026-08-24 close
- Market cap$3.2B as of 2026-08-24
- 1-year return+171.9% 2025-08-22 close $10.30 → 2026-08-24 close $28.01
- P/En/a negative earnings
- Net margin-1687.1% as of 2026-08-24
- ROE-51.1% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue growth (YoY)-63.3% as of 2026-08-24
- Revenue CAGR (3y)-29.6% SEC XBRL
- Beta1.65 as of 2026-08-24
- Last reported earnings2026-08-11 SEC EDGAR Form 8-K (Item 2.02)
How IMNM compares in its sector
- net profit marginbottom 25% 504 covered Health Care peers, as of 2026-08-24
- operating marginbottom 25% 504 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRbottom 10% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
IMNM is in the Health Care Short-term Top 10.
Health Care Short-term Top 10 — since 18 Aug 2026
Long-term score
38.3 #1384 of 1,605 scored · #162 of 195 in Health Care
Financial health 95th (debt to equity 0) and long-term trend 88th (a strong uptrend, with buyers in control); weakest is growth (1st, 3-year revenue CAGR -29.6%, revenue growth year over year -63.3%).
Short-term score
69.6 #10 of 1,698 scored · #5 of 236 in Health Care
Catalysts 91st: open-market insider buys in 90 days 30, the analyst consensus rating has improved toward "buy" since the prior reading; trend 83rd: a strong uptrend, with buyers in control; weakest is setup 46th: day-to-day price swings are unusually wide versus its own recent history (wider than about 84% of the past ~6 months). It is heavily shorted, but it also meets the short-squeeze screen, so no deduction applies.
In this list since 18 Aug 2026 — currently 2nd in the list (3 days)
- Entered 18 Aug 2026: first selection for this list at rank 6, score 67.3.
Scores as of 24 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 3.
How IMMUNOME INC looks technically
IMMUNOME INC (IMNM) is trading 29.0% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 247 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 43, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 62, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 4 trading days ago.
Trend
8
| Distance from the 200-day | it is trading 29.0% above its 200-day average, the long-term trend line — a longer-term uptrend | +29.0% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $23.27 | $23.27 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $21.72 | $21.72 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 38 calendar days ago — the swings before that are what the structure reading is measured on | 38 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes below 21.59. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible upward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 247 trading days ago — a "golden cross", a bullish long-term signal | 247 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 43, with buyers in control | 42.6 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 62, neither overbought (above 70) nor oversold (below 30) | 61.7 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($24.49 to $30.06) — its "stochastic" reading is 63 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 63.2 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 15 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $30.06 | $30.06 |
|---|---|---|
| From the 52-week high | it is 6.8% below its 52-week high (its highest price of the past year) | -6.8% |
| Above the 52-week low | it is 223.3% above its 52-week low (its lowest price of the past year) | +223.3% |
| Below the 52-week high | it is 6.8% below its highest point of the past year | 6.8% |
| Since a 20-day breakout | it made a new 20-day high about 4 trading days ago | 4 sessions |
| Since a 55-day breakout | it made a new 55-day high about 4 trading days ago | 4 sessions |
| All-time high | its highest closing price on record is $48.70 (set on 2021-02-24) | $48.70 |
| Given back of the 52-week move | over the past year its closes ranged ($8.99 to $29.82), and it has given back only a small part of its rise from last year’s low — 9% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $16.28 to $16.95. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 8.7% |
| From the all-time high | it is 42.5% below its all-time high | -42.5% |
| Nearest price level | it is trading 10.5% above a support level at $25.07 — a price it turned at three times since 2025-12-15, most recently on 2026-07-07. Since 2024-08-26 it has 16 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -10.5% |
| All-time low | its lowest closing price on record is $2.09 (set on 2022-05-11) | $2.09 |
| Above the all-time low | it is 1240.2% above its all-time low | +1,240% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 84% of the past ~6 months) | 84th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.44 between its high and its low — about 5.1% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.44 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $21.84 and $30.12 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $21.84 – $25.98 – $30.12 |
| Typical daily range (% of price) | its price moves about 5.1% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.1% |
| Stretch from the 200-day average | it is trading 4.4 daily ranges above its 200-day average price (29.0% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 4.4 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.88× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 1.5% since the prior reading | +1.5% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating has improved toward "buy" since the prior reading | 0.02 toward buy |
Candlestick patterns
2
| Since a doji | 1 session ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 1 session ago |
|---|---|---|
| Since a bearish engulfing | today it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | today |
Price gaps
3
| Gap at the open | it opened on 2026-08-24 0.8% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.8% |
|---|---|---|
| Open gap | it gapped 2.3% below the previous close 2 sessions ago and has not traded back through the level it left behind at 29.83 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -2.3% |
| Gap filled | a 2.2% gap up opened on 2026-08-13 has been "filled" 7 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 7 sessions ago |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 22.8 percentage points (the stock gained 26.1% while the market gained 3.3%) | +22.8% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 26.9 percentage points (the stock gained 29.3% while the market gained 2.4%) | +26.9% |
| vs market, 6 months | over the past 6 months this stock beat the market by 15.6 percentage points (the stock gained 26.6% while the market gained 11.1%) | +15.6% |
| vs market, 12 months | over the past 12 months this stock beat the market by 153.6 percentage points (the stock gained 171.9% while the market gained 18.3%) | +153.6% |
Signal agreement
2
| Bullish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
|---|---|---|
| Bearish technical signals | 0 of the 9 technical signals we can compute for it are currently in a bearish state — these describe past price behaviour, not a forecast | 0 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 25% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-17 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 3.4% of the share price. | +25.3% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 25% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $22.33 — a volume-weighted average of daily closes over 156 sessions, not a true tick-by-tick VWAP. | +25.4% |
|---|---|---|
| Vs the average paid since it last reported | the price is sitting right on the average price paid since it last reported on 2026-08-11 (its 10-Q), so the typical buyer over that stretch is roughly break-even. That average is $28.10 — a volume-weighted average of daily closes over 10 sessions, not a true tick-by-tick VWAP. | -0.3% |
Price levels it has turned at before
IMNM last closed at $28.01 on 2026-08-24. Since 2024-08-26 it has turned at 16 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $25.07 | Support | 10.5% below the last close | turned there three times · 2025-12-15 to 2026-07-07 |
| $23.84 | Support | 14.9% below the last close | turned there twice · 2026-01-30 to 2026-05-05 |
| $23.21 | Support | 17.1% below the last close | turned there twice · 2026-04-01 to 2026-05-21 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes below $21.59.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $28.76 and $33.19 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close below $21.59.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-24.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · in a strong, established uptrend (ADX) · Analyst price target recently RAISED · beating the market · Printed a bearish engulfing pair · Trading above the Ichimoku cloud | Learn: moving average · golden cross · adx · rsi · breakout
Based on daily closing prices as of 2026-08-24. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.21 mean, 1=Strong Buy…5=Strong Sell) — 13 analysts
- Mean price target$36.31 range $30.00 – $40.00; median $36.00
Analyst estimates, as of 2026-08-21. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for IMNM
- Consensus EPS estimate-$0.5048 next reporting period, as of 2026-08-21
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["History of significant operating losses and expectation of continued losses as research and development expenses remain high.","Dependence on success of clinical-stage or preclinical product candidates which may fail to demonstrate efficacy or safety.","Risk of failure to raise additional capital, which may be required for future operations."]
What changed in the latest 10-Q
AI-assisted comparison of IMNM's 10-Q filed 2026-05-12 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Added:
- Varegacestat announced positive topline results from Phase 3 RINGSIDE trial in December 2025 with specific efficacy data (84% reduction in progression-free survival risk, HR=0.16, p<0.0001; 56% ORR vs. 9% placebo)
- NDA for varegacestat submitted in April 2026 with planned MAA submission to EMA by end of 2026
- IM-1021 reported observed objective responses in B-cell lymphoma patients in November 2025
- IM-1021 incorporates HC74 proprietary TOP1i payload and may provide improved therapeutic index
- IM-3050 initiated first site for Phase 1 trial in March 2026 in patients with FAP-expressing solid tumors
- IM-1617 received initial IND clearance in April 2026 with planned Phase 1 initiation in Q2 2026
- IM-1617 described as first-in-class ADC targeting undisclosed receptor preferentially expressed in broad array of solid tumors
- Preclinical assets include two solid tumor ADCs (IM-1340 and IM-1335) with anticipated 2026 IND submissions
- Pipeline includes numerous early-stage ADCs from internal discovery with opportunities for additional IND submissions in 2027 and beyond
- HC74 is described as differentiated novel topoisomerase 1 (TOP1) inhibitor payload supporting discovery strategy
- Company committed to development of first-in-class and best-in-class targeted oncology therapies with deep expertise in antibody-drug conjugates
- Removed:
- Description of company as 'clinical-stage targeted oncology company' (replaced with 'biotechnology company')
- Reference to December 31, 2024 in Form 10-K reference (updated to December 31, 2025)
- Statement that varegacestat was 'currently under evaluation in a Phase 3 clinical trial' (now Phase 3 completed with results reported)
- Expectation to report Phase 3 topline data 'in the second half of 2025' (now reported in December 2025)
- Statement that IM-1021 had 'first patient dosed in February 2025' (removed from newer filing)
- Preclinical data on IM-1021 showing 'sustained tumor regression in mouse models of TNBC and MCL' (removed from newer filing)
- Statement that IM-3050 'received IND clearance in April 2025 and plan to initiate Phase 1 trial in early 2026 after delivery of third-party diagnostic radiotracer supply' (updated to March 2026 initiation)
- IND-enabling work description for IM-1617 'is ongoing' (replaced with IND clearance received April 2026 and Q2 2026 Phase 1 initiation plan)
- Reference to three preclinical assets and expectation of '2026 IND submissions' for three ADCs (IM-1617, IM-1340, IM-1335) (updated to two preclinical assets with IM-1617 now clinical)
- Statement about 'multiple ADCs currently undergoing lead optimization in advance of future development decisions' (replaced with 'numerous early-stage ADCs')
- Reworded:
- Company description changed from 'clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted therapies designed to improve outcomes for cancer patients' to 'biotechnology company committed to the development of first-in-class and best-in-class targeted oncology therapies' with goal to 'improve the lives of cancer patients'
- Overview reference to Form 10-K changed from 'year ended December 31, 2024' to 'year ended December 31, 2025'
- Pipeline composition changed from 'three clinical assets and three preclinical assets' to 'four clinical assets and two preclinical assets'
- Varegacestat description changed from 'oral, once daily GSI' to 'investigational, oral, once-daily gamma secretase inhibitor, or GSI'
- IM-1021 data presentation changed from 'We expect to present initial data for IM-1021 in 2026' to 'We plan to share initial lymphoma data in 2026'
- IM-3050 trial status changed from 'plan to initiate a Phase 1 trial in early 2026 after delivery of third-party diagnostic radiotracer supply' to 'initiated the first site for a Phase 1 trial in March 2026'
- HC74 acquisition context added: 'purchased from Zentalis Pharmaceuticals, Inc., or Zentalis, in October 2024' reference removed; described as supporting strategy for designing ADCs against novel targets
- Varegacestat data presentation now includes specific Phase 3 RINGSIDE results with confirmed ORR and median best change in tumor volume alongside Phase 2 data
- Notes:
- The newer filing text is truncated at the IM-1617 section ('The target is a receptor tyrosine kinase that promotes tumor cell survival a') and may not represent the complete section.
- The older filing text is also truncated at the IM-1340 section ('It has a unique ex') and may not represent the complete section.
- Comparison is limited by the truncation of both source documents, potentially missing additional changes in sections not fully provided.
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
3 open-market purchases and 15 open-market sales by insiders in the last 90 days.
- Last 30 days0 buys · 1 sell ($2M) — 1 selling insider
- Last 90 days3 buys ($204260) · 15 sells ($13M) — 1 buying, 5 selling insiders
- Last 180 days4 buys ($307760) · 15 sells ($13M) — 1 buying, 5 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-04. As of 2026-08-25.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about IMNM's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding IMNM as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 30,783,128
- Reported value $673,227,011
reported quarterly holdings change (2025-12-31 → 2026-03-31): 1 new, 3 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
IMNM had 17,981,724 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
IMNM had 15.8% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 22.98 days to cover at the same settlement.
- Reported short interest (shares) 17,981,724
- Short interest (% of shares outstanding) 15.8%
- Prior settlement (shares) 17,237,765
- Reported change 4.32%
- Days to cover (reported) 22.98
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Regeneron Pharmaceuticals (REGN)
- Seagen (acquired by Pfizer)
- Genmab (GMAB)
- Gilead Sciences (GILD)
- AstraZeneca (AZN)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare IMNM vs…
IMMUNOME INC is found in…
Frequently asked questions
What does IMMUNOME INC (IMNM) do?
Immunome is a biotechnology company focused on the discovery and development of targeted oncology therapies. The company utilizes a proprietary technology platform to identify and develop novel antibody-based treatments for cancer.
What sector is IMMUNOME INC (IMNM) in?
IMMUNOME INC (IMNM) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Who are IMMUNOME INC's (IMNM) competitors?
Notable peers of IMMUNOME INC (IMNM) include Regeneron Pharmaceuticals, Seagen (acquired by Pfizer), Genmab, Gilead Sciences and AstraZeneca. This peer set is informational only — not financial advice.
Is IMMUNOME INC (IMNM) overbought or oversold right now?
IMMUNOME INC (IMNM) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 62, in the neutral middle (as of 2026-08-24). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on IMNM come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-24.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.